McKenna Claire, Soares Marta, Claxton Karl, Bojke Laura, Griffin Susan, Palmer Stephen, Spackman Eldon
Centre for Health Economics, University of York, York, North Yorkshire, UK.
Centre for Health Economics, University of York, York, North Yorkshire, UK.
Value Health. 2015 Sep;18(6):865-75. doi: 10.1016/j.jval.2015.05.003. Epub 2015 Aug 13.
The key principles regarding what assessments lead to different types of guidance about the use of health technologies (Only in Research, Approval with Research, Approve, or Reject) provide an explicit and transparent framework for technology appraisal.
We aim to demonstrate how these principles and assessments can be applied in practice through the use of a seven-point checklist of assessment.
The value of access to a technology and the value of additional evidence are explored through the application of the checklist to the case studies of enhanced external counterpulsation for chronic stable angina and clopidogrel for the management of patients with non-ST-segment elevation acute coronary syndromes.
The case studies demonstrate the importance of considering 1) the expected cost-effectiveness and population net health effects; 2) the need for evidence and whether the type of research required can be conducted once a technology is approved for widespread use; 3) whether there are sources of uncertainty that cannot be resolved by research but only over time; and 4) whether there are significant (opportunity) costs that once committed by approval cannot be recovered.
The checklist demonstrates that cost-effectiveness is a necessary but not sufficient condition for approval. Only in Research may be appropriate when a technology is expected to be cost-effective due to significant irrecoverable costs. It is only approval that can be ruled out if a technology is not expected to be cost-effective. Lack of cost-effectiveness is not a necessary or sufficient condition for rejection.
关于何种评估会导致对卫生技术使用的不同类型指导(仅用于研究、批准并开展研究、批准或拒绝)的关键原则,为技术评估提供了一个明确且透明的框架。
我们旨在通过使用一份七点评估清单来展示这些原则和评估如何在实践中应用。
通过将该清单应用于慢性稳定型心绞痛的增强型体外反搏和非ST段抬高型急性冠状动脉综合征患者管理中的氯吡格雷的案例研究,探讨获取一项技术的价值和额外证据的价值。
案例研究表明了考虑以下方面的重要性:1)预期的成本效益和人群净健康影响;2)对证据的需求以及一旦一项技术被批准广泛使用后所需研究类型是否能够开展;3)是否存在无法通过研究解决而只能随时间解决的不确定性来源;4)是否存在一旦批准就无法收回的重大(机会)成本。
该清单表明成本效益是批准的必要但非充分条件。当一项技术由于重大不可收回成本而预计具有成本效益时,仅用于研究可能是合适的。如果一项技术预计不具有成本效益,那么唯一可以排除的就是批准。缺乏成本效益不是拒绝的必要或充分条件。